Guerbet: Changes in Guerbet's Board of Directors
26 Mayo 2023 - 10:29AM
Guerbet: Changes in Guerbet's Board of Directors
Changes in Guerbet's Board of
Directors
- Appointment of Didier Izabel as Chair of the Board of
Directors
- Appointment of Pascale Auger as an Independent Director
- Renewal of three directorships
Villepinte, 26 May 2023:
Guerbet (FR0000032526 GBT), a world specialist in
contrast products and solutions for medical imaging, announces,
following the Annual General Meeting of 26 May 2023 and a Board of
Directors meeting held on the same day:
- the appointment of Didier Izabel as Chair of the Board
of Directors;
- the appointment of Pascale Auger as an
Independent Director;
- the renewal of the terms of office of three directors,
Carine Dagommer, Eric Guerbet and Thibault
Viort.
Didier Izabel, new Chair of the Board of
Directors of Guerbet
The Board of Directors appointed Mr Izabel, an
Independent Director since 2014, on the recommendation of the
Appointments and Remuneration Committee, as Chair. He succeeds
Marie-Claire Janailhac-Fritsch, Chair of the Guerbet Board since
2013, whose term of office has expired.
Didier Izabel, a graduate of
École Polytechnique and Ingénieur des Mines, joined Guerbet's Board
of Directors in 2014 as an Independent Director. A Senior Partner
at Axys Finance since 2009, Didier Izabel began his career at the
Ministry of Industry, where he was responsible for the
pharmaceutical industry for three years. He then spent his entire
career in investment banking, successively with Banexi (BNP Group),
Edmond de Rothschild, Toulouse & Associés and Banca
Leonardo.
"It is with great pride and responsibility
that I take on this new role entrusted to me by the Board. First
and foremost, I would like to pay tribute to Marie-Claire
Janailhac-Fritsch for her ten years as Chair of the Guerbet Board
and thank her for her commitment.”
Pascale Auger, new Independent Director
of Guerbet
The Annual General Meeting appointed Pascale
Auger as an Independent Director for a term of five
years.Pascale Auger, a graduate of Centrale Lille
and holder of a doctorate in robotics and industrial organisation
from the University of Lille, is Chair of the PRODEVAL Board of
Directors. She is also an independent director of ICAPE and Chair
of the Nominations, Remuneration and Governance Committee, and an
Independent Director and Chair of the Audit Committee of Exel
Industries. Pascale Auger began her career as a Partner at PwC in
charge of the industry and distribution sectors. She then became
Vice-Chair of Capgemini Consulting and successively held executive
positions with the Bolloré Group, AKKA Technologies, LafargeHolcim
and Rabot Dutilleul.
"I am honoured to join the Board of Directors of
Guerbet, a fine family-owned intermediate-sized enterprise in the
healthcare sector. The next few years will be important for the
Group's development and growth. I'm looking forward to being part
of this adventure.”
Renewal of three directorships: Carine
Dagommer, Eric Guerbet and Thibault Viort
The Guerbet General Meeting also renewed the
terms of office of three directors:
- Carine Dagommer, member of the Board of Directors since 2021,
Director representing the majority shareholder, for a term of 5
years;
- Éric Guerbet, member of the Board of Directors since 2017,
Director representing the majority shareholder, for a term of 6
years;
- Thibault Viort, member of the Board of Directors since 2017,
Independent Director, for a term of 1 year.
With effect from 26 May 2023, the Board of
Directors will comprise:
Didier Izabel*, Chair of the Board
Directors: Pascale Auger*, Carine Dagommer,
Olivier Fougère**, Mark Fouquet, Eric Guerbet, Céline Lamort,
Nicolas Louvet, Claire Massiot-Jouault, Marc Massiot,
Jean-Sébastien Raynaud** and Thibault Viort*
*Independent directors**Salaried directors
About Guerbet
At Guerbet, we build lasting relationships so
that we enable people to live better. That is our purpose. We are a
leader in medical imaging worldwide, offering a comprehensive range
of pharmaceutical products, medical devices, and digital and AI
solutions for diagnostic and interventional imaging. A pioneer in
contrast media for 95 years, with more than 2,600 employees
worldwide, we continuously innovate and devote 10% of our sales to
research and development in five centers in France, Israel, and the
United States. Guerbet (GBT) is listed on Euronext Paris (segment
B – mid caps) and generated €753 million in revenue in 2022.
- 26 05 2023_Changes in Guerbet's BoD
Guerbet (EU:GBT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Guerbet (EU:GBT)
Gráfica de Acción Histórica
De May 2023 a May 2024